Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 8/20 | 0.60 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | RIPK3 | Q9Y572 | 5/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3357875 | 0.88 | CSNK1E (0.68) | CSNK1EDYRK3CCNT1CDK9DYRK1A | |
| SCHEMBL3356325 | 0.86 | CSNK1E (0.62) | CSNK1EDYRK3CCNT1CDK9DYRK1A | |
| SCHEMBL3356116 | 0.86 | CSNK1E (0.62) | CSNK1EDYRK3CCNT1CDK9DYRK1A | |
| SCHEMBL3358558 | 0.85 | CSNK1E (0.81) | CSNK1EDYRK3CCNT1CDK9DYRK1A | |
| SCHEMBL3356273 | 0.82 | RIPK3 (0.43) | CSNK1ERIPK3 | |
| SCHEMBL3357408 | 0.80 | CSNK1E (0.72) | CSNK1EENPP2 | |
| SCHEMBL3355278 | 0.80 | CSNK1E (0.57) | CSNK1EDYRK3CCNT1CDK9DYRK1A | |
| SCHEMBL3356959 | 0.78 | CSNK1E (0.68) | CSNK1ERIPK3HRH3ENPP2 | |
| SCHEMBL1745927 | 0.78 | CSNK1E (0.92) | CSNK1EDYRK3CCNT1CDK9DYRK1A | |
| SCHEMBL3119317 | 0.76 | CSNK1E (0.77) | CSNK1EDYRK3CCNT1CDK9DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108971-B2 | 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof | SANOFI (FR) | 2015-08-18 | — | — | US | claimed |
| US-20130245023-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI (FR) | 2013-09-19 | — | — | US | claimed |
| EP-2178879-B1 | 6-CYCLOAMINO-S-(PYRIDAZIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2013-07-03 | — | — | EP | claimed |
| US-8455491-B2 | 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine and derivatives and pharmaceutical compositions comprising the same | SANOFI (FR) | 2013-06-04 | — | — | US | claimed |
| US-20100152157-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-17 | — | — | US | claimed |
| US-9108971-B2 | 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof | SANOFI (FR) | 2015-08-18 | — | — | US | disclosed |
| US-20130245023-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI (FR) | 2013-09-19 | — | — | US | disclosed |
| EP-2178879-B1 | 6-CYCLOAMINO-S-(PYRIDAZIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2013-07-03 | — | — | EP | disclosed |
| US-8455491-B2 | 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine and derivatives and pharmaceutical compositions comprising the same | SANOFI (FR) | 2013-06-04 | — | — | US | disclosed |
| US-20100152157-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245023-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | TLR7, IFNAR1, CBR3 | CSNK1E 757/4885DYRK3 2509/4885CCNT1 959/4885 |
| US-20100152157-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | IFNAR1, TLR7, CBR3 | CSNK1E 724/4885DYRK3 2484/4885CCNT1 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.